242 related articles for article (PubMed ID: 38338729)
1. Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance.
Kook E; Chun KS; Kim DH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338729
[TBL] [Abstract][Full Text] [Related]
2. YES1: A Novel Therapeutic Target and Biomarker in Cancer.
Garmendia I; Redin E; Montuenga LM; Calvo A
Mol Cancer Ther; 2022 Sep; 21(9):1371-1380. PubMed ID: 35732509
[TBL] [Abstract][Full Text] [Related]
3. YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
Takeda T; Yamamoto H; Suzawa K; Tomida S; Miyauchi S; Araki K; Nakata K; Miura A; Namba K; Shien K; Soh J; Shien T; Kitamura Y; Sendo T; Toyooka S
Cancer Sci; 2020 Mar; 111(3):849-856. PubMed ID: 31856375
[TBL] [Abstract][Full Text] [Related]
4. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.
Je DW; O YM; Ji YG; Cho Y; Lee DH
Pancreas; 2014 Jul; 43(5):768-76. PubMed ID: 24763074
[TBL] [Abstract][Full Text] [Related]
6. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
7. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
8.
Fan PD; Narzisi G; Jayaprakash AD; Venturini E; Robine N; Smibert P; Germer S; Yu HA; Jordan EJ; Paik PK; Janjigian YY; Chaft JE; Wang L; Jungbluth AA; Middha S; Spraggon L; Qiao H; Lovly CM; Kris MG; Riely GJ; Politi K; Varmus H; Ladanyi M
Proc Natl Acad Sci U S A; 2018 Jun; 115(26):E6030-E6038. PubMed ID: 29875142
[TBL] [Abstract][Full Text] [Related]
9. Role of YES1 signaling in tumor therapy resistance.
Zhou H; Sun D; Tao J; Xu M; Zhang X; Hou H
Cancer Innov; 2023 Jun; 2(3):210-218. PubMed ID: 38089407
[TBL] [Abstract][Full Text] [Related]
10. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
[TBL] [Abstract][Full Text] [Related]
11. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
[TBL] [Abstract][Full Text] [Related]
12. YES1 Is a Targetable Oncogene in Cancers Harboring
Hamanaka N; Nakanishi Y; Mizuno T; Horiguchi-Takei K; Akiyama N; Tanimura H; Hasegawa M; Satoh Y; Tachibana Y; Fujii T; Sakata K; Ogasawara K; Ebiike H; Koyano H; Sato H; Ishii N; Mio T
Cancer Res; 2019 Nov; 79(22):5734-5745. PubMed ID: 31391186
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
[TBL] [Abstract][Full Text] [Related]
14. Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation.
Pang Y; Liu Z; Han H; Wang B; Li W; Mao C; Liu S
J Hepatol; 2020 Nov; 73(5):1155-1169. PubMed ID: 32461121
[TBL] [Abstract][Full Text] [Related]
15. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases.
Cheng HC; Johnson TM; Mills RD; Chong YP; Chan KC; Culvenor JG
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):93-101. PubMed ID: 19566834
[TBL] [Abstract][Full Text] [Related]
16. YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer.
Wang L; Wang Q; Xu P; Fu L; Li Y; Fu H; Quan H; Lou L
Br J Cancer; 2020 Sep; 123(6):1000-1011. PubMed ID: 32572172
[TBL] [Abstract][Full Text] [Related]
17. EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis.
Mao L; Yuan W; Cai K; Lai C; Huang C; Xu Y; Zhong S; Yang C; Wang R; Zeng P; Huang H; Chen Z; Chen Z
Oncogene; 2021 May; 40(20):3610-3623. PubMed ID: 33941853
[TBL] [Abstract][Full Text] [Related]
18. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
Chen L; Cao H; Feng Y
World J Urol; 2018 Mar; 36(3):357-365. PubMed ID: 29204706
[TBL] [Abstract][Full Text] [Related]
19. Src family kinases in tumor progression and metastasis.
Summy JM; Gallick GE
Cancer Metastasis Rev; 2003 Dec; 22(4):337-58. PubMed ID: 12884910
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
Wang W; Marsh S; Cassidy J; McLeod HL
Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
